Fed’s Chris Waller Says September FOMC Decision to Depend on August Inflation Data
Artivion SVP Andrew Green sells $17,586 of common stock By Investing.com
- Investing
Ramit Sethi- 3 minutes read
Andrew M. Green, Senior Vice President of Regulatory and Quality at ARTIVION, INC. (), sold common stock totaling $17,586 on August 14, 2026.
The transaction involved the disposition of 616 shares at a price of $28.549 per share. According to the filing, these shares were sold upon the vesting of restricted stock units to cover tax withholding obligations. This indicates a non-discretionary transaction, used to satisfy tax withholding obligations through a “sell to cover” mechanism.
Following this transaction, Mr. Green directly holds 59,643 shares of ARTIVION common stock.The transaction comes as ARTIVION shares have posted a significant return of nearly 11% over the past week, according to InvestingPro data. The stock currently trades above its Fair Value estimate, placing it on InvestingPro’s Most Overvalued list. For deeper insights into ARTIVION’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Artivion Inc. reported second-quarter revenue of $125.8 million, marking a 9% increase on a constant-currency basis. This figure surpassed Wall Street’s forecast of $120.06 million and Canaccord’s estimate of $119.3 million. The growth was driven by strong performance in stent grafts and On-X heart valves, although BioGlue sales were softer. Adjusted EBITDA came in at $26.4 million, exceeding both Canaccord’s estimate of $21.6 million and the consensus of $21.7 million. The company has maintained its fiscal 2026 guidance, indicating confidence in its long-term strategy.
Additionally, Artivion’s acquisition of Endospan and the PMA approval for AMDS were highlighted as significant developments by Canaccord, which raised its price target for the company from $36 to $39 while maintaining a Buy rating. These recent achievements suggest a positive outlook for Artivion, according to Canaccord’s analysis. The company did not release EPS figures, but the revenue beat and strategic advancements have been well-received by investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
